[{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : MIN-102 (leriglitazone) is Minoryx’s novel orally bioavailable and selective PPARγ agonist with a potential first-in-class and best-in-class profile for adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy.

                          Product Name : MIN-102

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 06, 2023

                          Lead Product(s) : Leriglitazone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Treatment with leriglitazone demonstrated PPARg engagement in all patients within the target range required for efficacy as assessed by a biomarker (adiponectin).

                          Product Name : MIN-102

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 26, 2021

                          Lead Product(s) : Leriglitazone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.

                          Product Name : MIN-102

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 30, 2020

                          Lead Product(s) : Leriglitazone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : European Investment Bank

                          Deal Size : $29.0 million

                          Deal Type : Funding

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.

                          Product Name : MIN-102

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 23, 2020

                          Lead Product(s) : Leriglitazone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Sperogenix Therapeutics

                          Deal Size : $78.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.

                          Product Name : Albutein

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2020

                          Lead Product(s) : Perflutren,Immunoglobulin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank